RANKing c-Jun in osteoclast development
- 16 August 2004
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 114 (4), 463-465
- https://doi.org/10.1172/jci200422644
Abstract
Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the JCI documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 .This publication has 22 references indexed in Scilit:
- Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defectsThe Journal of cell biology, 2004
- Osteoclast differentiation and activationNature, 2003
- Regulation of the Murine Nfatc1 Gene by NFATc2Journal of Biological Chemistry, 2002
- Partners in transcription: NFAT and AP-1Oncogene, 2001
- Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK ActivationJournal of Biological Chemistry, 2001
- TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligandJournal of Clinical Investigation, 2000
- Bone Resorption by OsteoclastsScience, 2000
- Fosl1 is a transcriptional target of c-Fos during osteoclast differentiationNature Genetics, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- The Upper Colorado 1Nature, 1877